Medicinova Inc (MNOV) 10-Q Quarterly Report October 2018

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2018	Oct. 24, 2018
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q3
Trading Symbol	MNOV
Entity Registrant Name	MEDICINOVA INC
Entity Central Index Key	0001226616
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		41,881,306

Please wait while we load the requested 10-Q report or click the link below:

https://last10k.com/sec-filings/report/1226616/000156459018025127/mnov-10q_20180930.htm

View differences made from one quarter to another to evaluate Medicinova Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Medicinova Inc.

Continue

Assess how Medicinova Inc's management team is paid from their Annual Proxy

Medicinova Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:

Voting Procedures
Board Members
Executive Team
Salaries, Bonuses, Perks
Peers / Competitors

Continue

Rating
Learn More

Filter Sentiment:

All

Positive

Negative

Filter Category:

All

Financial

Revenue

Other

Filter Subcategory:

All

Income

Expense

Geography

Product

Other

Inside Medicinova Inc's 10-Q Quarterly Report:

Financial - Income Highlight
The criteria used for these evaluations include managements estimate of the assets continuing ability to generate income from operations and positive cash flows in future periods as well as the strategic significance of any intangible assets in our business objectives.

Financial - Shares Highlight
Additionally, we granted the underwriters a 30-day option to purchase up to an additional 662,983 shares of commons stock at the public offering price, and on February 21, 2018, we sold an additional 126,038 shares of common stock for gross proceeds of $1.1 million pursuant to the partial exercise by the underwriters of their over-allotment option.
Financial - Shares Highlight
In the absence of an observable market price for the stock award, the grant date fair value of the award would be based upon a valuation methodology that takes into consideration various factors, including the exercise price of the award, the expected term of the award, the current price of the underlying shares, the expected volatility of the underlying share price, the expected dividends on the underlying shares and the risk-free interest rate.
Financial - Shares Highlight
Net cash provided by financing activities during the nine months ended September 30, 2018 is primarily due to the public offering of 4,545,928 shares of common stock for net proceeds of approximately $38.5 million and cash proceeds of $2.4 million from the exercise of warrants to purchase 750,000 shares of common stock.
Financial - Expense Highlight
The $2.3 million increase was due to increased clinical research study costs for MN-166 as well as higher stock compensation expense for performance-based stock options due to an increase in our stock price.
Financial - Expense
On an on-going basis, we...Read more
Financial - Shares
On February 12, 2018, we...Read more
Financial - Expense
Research, development and patents costs...Read more
Financial - Expense
Our research, development and patents...Read more
Revenue - Geography
In October 2011, we entered...Read more
Revenue - Product
No revenue was recognized in...Read more
Financial - Expense
Our general and administrative costs...Read more
Financial - Expense
Internal research and development expenses...Read more
Other - Other
As a result, we are...Read more
Other - Other
We do not have relationships...Read more
Financial - Expense
Our general and administrative expenses...Read more
Other - Other
For example, we contributed financially...Read more
Other - Other
Valuation of our stock option...Read more
Revenue - Product
The amount received from Kissei...Read more

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Material Contracts, Statements, Certifications & more

Medicinova Inc provided additional information to their SEC Filing as exhibits

Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 32.1: Section 1350 Certification

Exhibit 32.2: Section 1350 Certification

Ticker: MNOV
CIK: 1226616
Form Type: 10-Q Quarterly Report
Accession Number: 0001564590-18-025127
Submitted to the SEC: Thu Oct 25 2018 12:17:14 PM EST
Accepted by the SEC: Thu Oct 25 2018
Period: Sunday, September 30, 2018
Industry: Pharmaceutical Preparations